Travere Therapeutics announced the FDA granted accelerated approval to Filspari, also known as sparsentan, according to a company press release.
Filspari is a once-daily oral medication designed to reduce proteinuria in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. The medication is the first and only non-immunosuppressive therapy approved for this condition.
“The accelerated approval of [Filspari] is a significant milestone on our path to advancing a transformative treatment for the IgA nephropathy community,” Eric Dube, PhD, president and chief